OR WAIT null SECS
RAPID’s artificial intelligence (AI) software aids clinicians in diagnosing and treating stroke victims more quickly.
The U.S. Food and Drug Administration (FDA) has cleared iSchemaView’s RAPID neuroimaging platform for use in selecting acute stroke patients who are likely to benefit from endovascular thrombectomy, according to iSchemaView’s announcement today.
RAPID, developed by stroke experts, uses artificial intelligence (AI) framework that, according to iSchemaView, combines expert feature extraction and proprietary algorithms to identify stroke patients that should get their clot removed. The software aids clinicians in diagnosing and treating stroke victims more quickly.
Because of the clearance, RAPID computed tomography (CT)-Perfusion and RAPID magnetic resonance (MR)-Perfusion can be used by physicians to help select acute stroke patients with known obstruction of the internal carotid artery or proximal middle cerebral artery for a clot removal procedure.
According to the company, RAPID is the only imaging platform approved for selecting stroke patients for clot removal.
CEO of iSchemaView, Don Listwin, said the clearance will benefit smaller hospitals.
The software enables stroke treatment decisions by providing easily interpretable real-time views of brain perfusion. Physicians will be able to determine lesion volumes for a wide variety of different thresholds.
“…Physicians will quickly and easily be able to determine which patients can be treated locally and which require urgent transfer to thrombectomy centers — bolstering the capabilities of smaller hospitals and therefore improving patient care,” Listwin said.
Expedient care is essential for stroke victims — waiting too long to identify the need for a procedure could be life-threatening.
The software is currently in use in more than 40 countries and over 1,000 hospitals.
Get the best insights in healthcare analytics directly to your inbox.